Opinion
Video
Author(s):
Hematologist-oncologists discuss the risk stratification of patients with myelodysplastic syndromes and how patient risk status determines prognosis.
FDA Approves Blinatumomab for CD19+ B-ALL in the Consolidation Phase
Camidge and Cooper on Finding Purpose and Embracing Nuance in Hospital Chaplaincy
Ponatinib Regimen Shows Long-term Efficacy in Acute Lymphoblastic Leukemia
Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC
Anemia Does Not Diminish Benefit With Ruxolitinib Treatment in Myelofibrosis
CD7-Directed CAR T-Cell Therapy WU-CART-007 Is Safe in R/R T-ALL/LBL
Earlier Use of Acalabrutinib Associated With Improved Survival in CLL
CAR T-Cell Therapy Is Safe, Feasible in Outpatient Setting for NHL
Englumafusp alfa/Glofitamab Combo Shows Early Responses in R/R Aggressive non-Hodgkin Lymphoma